SAFETY DATA EXCHANGE AGREEMENT between Biocon Pharma Limited 20th KM, Hosur Road, Electronics City P.O Bangalore 560 100 India (“BIOCON”) and China Medical System Holdings CMS Bridging DMCC Limited Unit No: 205-B, JBC1, Plot No: JLT- PH1-G2A, Jumeirah...Safety Data Exchange Agreement • October 14th, 2020
This Local Safety Data Exchange Agreement made effective on “Effective Date” by and between Biocon Pharma Limited, a company registered under the laws of India, having its registered office at 20TH KM Hosur Road, Electronics City Phase-1, Bangalore-560100 and CMS Bridging DMCCCMS Bridging Limited, a company organized and existing under the laws of UAEHong Kong (Registration No.: 2327427), having its principal place of business at Unit 2106, 21/F, Island Place Tower, No. 510 King’s Road, North Point, Hong Kong Unit No: 205-B, JBC1, Plot No: JLT-PH1-G2A, Jumeirah Lakes Towers, Dubai, UAE; and Shenzhen Kangzhe Pharmaceutical Co., Ltd., a company organized and existing under the laws of Mainland China, having its principal place of business at 6F, Block B, Majialong Chuangxin Building, 198 Daxin Road, Nantou Sub-district, Nanshan District, Shenzhen, P.R. China.
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • October 23rd, 2021 • Hong Kong
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • February 10th, 2020 • Hong Kong
SDEA) Between Sun Pharmaceutical Industries Ltd. SUN ……………… Limited [Name of SUN entity] (hereinafter called SUN) And Shenzhen Kangzhe Pharmaceutical Co.,Ltd. (hereinafter called CMS)Safety Data Exchange Agreement • February 26th, 2020
The Products [as listed in Appendix 1] are Products(as listed in Appendix I) are the subject of a License Agreements between CMS PharmaBRIDGING DMCC (“CMS Dubai”) and SUN (as defined below, the “Business Contracts”) covering specified Tterritories, whereby SUN will supply CMS, the Product(s)
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • April 19th, 2019
BIOCODEX S.A.S. (hereinafter "BIOCODEX"), a corporation with its principal offices located 7 avenue Gallieni, 94250 Gentilly, France, CMS Bridging Limited, Unit 2106, 21/F, Island Place Tower, 510 King's Road, North Point, Hong Kong (hereinafter "CMS Bridging") and Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”, together with “CMS Bridging” hereinafter referred to as “CMS”), a corporation having its registered office at 6F, Block B, Majialong Chuangxin Building, 198 Daxin Road, Nanshan District, Shenzhen, Guangdong Province, P.R. China, COMPANY (hereinafter "CMS"), a corporation with its principal offices located ADDRESS, entered into a contract agreement whereby CMS became responsible for activities in one or several countries (hereinafter "the Territory" – See Appendix 1) for one or more drug products (hereinafter "the Product" - See Appendix 1) on behalf of BIOCODEX who is the Marketing Authorization Holder (MAH) in the Territory.
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • September 13th, 2021
This Safety Data Exchange Agreement (“SDEA”) is made pursuant to the License Agreement dated November ? 2017 between PrincipalTP and DistributorASTRAZENECA (“License Agreement”) covering the Product(s) in the Territory.
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • January 21st, 2015
BIOCODEX S.A. (hereinafter "BIOCODEX"), a corporation with its principal offices located 7 avenue Gallieni, 94250 Gentilly, France and CMS Pharma Co., Ltd.CMS Pharmaceutical Co. Ltd (hereinafter "CMS"), a corporation with its principal offices located at Level 15(A2), 8/F, Bldg. A, Tongfang Information Harbor, No. 11 Langshan Road, Shenzhen Hi-tech Industrial Park North, Nanshan District, Shenzhen 518057, P. R. China Mai Office Tower, Financial Park Labuan Jalan Merdeka, 87000 Labuan F.T., Malaysia, entered into a contract agreement whereby CMS became responsible for activities in one or several countries (hereinafter "the Territory" – See Appendix 1) for one or more drug products (hereinafter "the Product" - See Appendix 1) on behalf of BIOCODEX who is the Marketing Authorization Holder in the Territory.
EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTSafety Data Exchange Agreement • July 31st, 2013 • Cempra, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of May 8, 2013 (the “Effective Date”) by and between CEMPRA PHARMACEUTICALS, INC., a Delaware corporation having an address at Building Four Quadrangle, 6340 Quadrangle Drive, Suite 100, Chapel Hill, North Carolina 27517 USA (“Cempra”), and TOYAMA CHEMICAL CO., LTD., a Japanese corporation having an address at 2-5, Nishishinjuku 3-chome, Shinjuku-ku, Tokyo 160-0023, Japan (“Toyama”). Cempra and Toyama may be referred to herein individually as a “Party” or collectively, as the “Parties.”
SAFETY DATA EXCHANGE AGREEMENTSafety Data Exchange Agreement • July 5th, 2021
BIOCODEX S.A.S. (hereinafter "BIOCODEX"), a corporation with its principal offices located 7 avenue Gallieni, 94250 Gentilly, France and CMS Bridging Limited, a corporation with its offices located Unit 2106, 21/F, Island Place Tower, 510 King's Road, North Point, Hong Kong (hereinafter "CMS Bridging") and Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”, together with “CMS Bridging” hereinafter referred to as “CMS”), a corporation having its registered office at 6F, Block B, Majialong Chuangxin Building, 198 Daxin Road, Nanshan District, Shenzhen, Guangdong Province, P.R. China, entered into a contract agreement whereby CMS became responsible for distribution, promotion and regulatory activities in one or several countries (hereinafter "the Territory" – See Appendix 1) for one or more drug products (hereinafter "the Product" - See Appendix 1) on behalf of BIOCODEX who is the Marketing Authorization Holder (MAH) in the Territory.
SDEA) Between Sun Pharma Global FZE LABORATOIRE UNITHER And CMS Address. (hereinafter called CMS Shenzhen Kangzhe Pharmaceutical Co.,Ltd. 6F - 8F, Block B, Majialong Chuangxin Building, 198 Daxin Road, Nanshan District, Shenzhen 518052, Guangdong...Safety Data Exchange Agreement • September 8th, 2020
The Product，s Cequa (Cyclosporine Eye Dropsas listed in Appendix 1) areis the subject of the License Agreement (effective date on DD-MM-YYYY) and the License Agreement (effective date on DD-MM-YYYY) between CMS and SUN (the “Business Contracts”) covering specified Territory, whereby SUN will supply CMS, or its designated Affiliate, the Product(s) for exploit, develop, use and Commercialization in the Territory.
